{"filing":{"accession_number":"0001140361-26-023093","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"ef20075060_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126023093/ef20075060_8k.htm"},"events":[{"id":8380,"run_id":7360,"accession_number":"0001140361-26-023093","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Ionis disclosed positive Phase 3 pivotal trial results for bepirovirsen, a partnered investigational drug for chronic hepatitis B licensed to GSK, demonstrating a 19% functional cure rate and meeting primary endpoints with clinical efficacy superior to standard of care. This material clinical milestone affects investor assessment of the company's pipeline prospects and partnership value.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2247,"accession_number":"0001140361-26-023093","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Ionis disclosed positive pivotal trial data for bepirovirsen, a partnered investigational drug for chronic hepatitis B, reported by GSK. While this is material clinical progress for a key pipeline asset, it does not fit neatly into the standard taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, or M\u0026A event. The disclosure is material to investors assessing the company's pipeline prospects and partnership value, but the event type is best classified as other_material given the absence of a dedicated category for clinical trial results or partnership milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:17:27.846199+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2248,"accession_number":"0001140361-26-023093","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Ionis announced positive Phase 3 trial results for bepirovirsen (a partnered asset licensed to GSK) showing a 19% functional cure rate in CHB treatment, meeting primary endpoints and demonstrating clinical efficacy superior to standard of care. While this is material news affecting investor assessment of the company's pipeline and partnership value, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release (no financial results), nor a specific material event category. The disclosure is appropriately classified as \"other_material\" given its significance to the registrant's therapeutic prospects and royalty potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:17:27.846199+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2247,"accession_number":"0001140361-26-023093","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Ionis disclosed positive pivotal trial data for bepirovirsen, a partnered investigational drug for chronic hepatitis B, reported by GSK. While this is material clinical progress for a key pipeline asset, it does not fit neatly into the standard taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, or M\u0026A event. The disclosure is material to investors assessing the company's pipeline prospects and partnership value, but the event type is best classified as other_material given the absence of a dedicated category for clinical trial results or partnership milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:17:27.846199+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-05-28"},{"id":2248,"accession_number":"0001140361-26-023093","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Ionis announced positive Phase 3 trial results for bepirovirsen (a partnered asset licensed to GSK) showing a 19% functional cure rate in CHB treatment, meeting primary endpoints and demonstrating clinical efficacy superior to standard of care. While this is material news affecting investor assessment of the company's pipeline and partnership value, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release (no financial results), nor a specific material event category. The disclosure is appropriately classified as \"other_material\" given its significance to the registrant's therapeutic prospects and royalty potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:17:27.846199+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-05-28"}]}